RDP Pharma AG, a biotechnology company focused on next-generation protein degradation therapeutics, today announced a strategic research collaboration with the Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development, to jointly discover and develop a monovalent targeted protein degrader for anti-inflammatory therapies.

ten23 health, the human-centric and sustainable strategic CDTMO partner of choice for the pharmaceutical industry and biotech start-ups, has joined the „Alliance for RTU“, an association to advance technical exchange for ready-to-use (RTU) containers in sterile manufacturing. The Alliance for RTU was formed in response to the market need for aseptic filling technologies and processes. It provi

Disease-Modifying Potential of Beech Biotech’s “Mother-Only” Antibody Programme and Platform Technology Further Underscored by Gates Foundation Grant

SOPHiA GENETICS has launched a new podcast series titled Decoded, hosted by CEO Dr. Jurgi Camblong. The series aims to make complex medical technologies, from AI-powered diagnostics to liquid biopsy, accessible and understandable to healthcare professionals and the wider public.

Brenus Pharma, a French biotech developing next-generation first-in-class immunotherapies, and InSphero, a Swiss leader in 3D cell-based assay technologies, presented promising data at the European Association for Cancer Research 2025 annual congress. These data confirm the use of 3D tumor spheroids for potency testing of STC-1010, Brenus’ lead candidate for colorectal cancer.

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced a summary of data that were presented at the European Academy of Allergy and Cl